Intravitreal injections: Does globe size matter? [7]

Journal of Cataract and Refractive Surgery

Volumn 28, Issue 10, 2002, Pages 1886-1889

  Teichmann, Klaus D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CEFAZOLIN; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; VANCOMYCIN;

APHAKIA; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG PENETRATION; DRUG TOLERANCE; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; EYE AXIS LENGTH; HUMAN; LETTER; MEDICAL LITERATURE; MINIMUM INHIBITORY CONCENTRATION; MYOPIA; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA; TREATMENT FAILURE; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

EID: 0036797756     PISSN: 08863350     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0886-3350(02)01671-1     Document Type: Letter

References (19)

1. Fechner PU, Teichmann KD. Ocular Therapeutics; Pharmacology and Clinical Application. Thorofare, NJ, Slack Inc, 1998; 11
2. Aguilar HE, Meredith TA, Al-Massry A, et al. Vancomycin levels after intravitreal injection; effects of inflammation and surgery. Retina 1995; 15:428-432
3. Fisher JP, Civiletto SE, Forster RK. Toxicity, efficacy, and clearance of intravitreally injected cefazolin. Arch Ophthalmol 1982; 100:650-652
4. Campochiaro PA, Green WR. Toxicity of intravitreous ceftazidime in primate retina. Arch Ophthalmol 1992; 110:1625-1629
5. Kawasaki K, Ohnogi J, Okayama Y. Nontoxic concentration of amphotericin B for intravitreal use - Evaluated by in vitro ERG. Documenta Ophthalmologica 1988; 69:19-23
6. Baldinger J, Doft BH, Burns SA, Johnson B. Retinal toxicity of amphotericin B in vitrectomized versus nonvitrectomized eyes. Br J Ophthalmol 1986; 70:657-661
7. Ficker L, Meredith TA, Gardner S, Wilson LA. Cefazolin levels after intravitreal injection; effects of inflammation and surgery. Invest Ophthalmol Vis Sci 1990; 31:502-505
8. Oztiirk F, Kortunay S, Kurt E, et al. Ofloxacin levels after intravitreal injection; effects of trauma and inflammation. Ophthalmic Res 1999; 31:446-451
9. Campochiaro PA, Conway BP. Aminoglycoside toxicity; a survey of retinal specialists. Implications for ocular use. Arch Ophthalmol 1991; 109:946-950
10. Doft BH, Weiskopf J, Nilsson-Ehle I, Wingard LM. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology 1985; 92:1601-1605
11. Pearson PA, Hainsworth DP, Ashton P. Clearance and distribution of ciprofloxacin after intravitreal injection. Retina 1993; 13:326-333
12. Talamo JH, D'Amico DJ, Hanninen LA, et al. The influence of aphakia and vitrectomy on experimental retinal toxicity of aminoglycoside antibiotics. Am J Ophthalmol 1985; 100:840-847
13. Callegan MC, Booth MC, Gilmore MS. In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens. Cornea 2000; 19:539-545
14. Davey PG, Barza M, Stuart M. Dose response of experimental Pseudomonas endophthalmitis to ciprofloxacin, gentamicin, and imipenem: evidence of resistance to "late" treatment of infections. J Infect Dis 1987; 155: 518-523
15. Irvine WD, Flynn HW Jr, Miller D, Pflugfelder SC. Endophthalmitis caused by gram-negative organisms. Arch Ophthalmol 1992; 110:1450-1454
16. Shaarawy A, Meredith TA, Kincaid M, et al. Intraocular injection of ceftazidime; effects of inflammation and surgery. Retina 1995; 15:433-438
17. Shaarawy A, Grand MG, Meredith TA, Ibanez HE. Persistent endophthalmitis after intravitreal antimicrobial therapy. Ophthalmology 1995; 102:382-387
18. Yoshizumi MO, Bhavsar AR, Dessouki A, Kashani A. Safety of repeated intravitreous injections of antibiotics and dexamethasone. Retina 1999; 19:437-441
19. Peyman GA. Discussion to McDonald, Schatz H, Allen AW, et al. Retinal toxicity secondary to intraocular gentamicin injection. Ophthalmology 1986; 93:871-877